SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, David R. Kaufman, Samir N. Khleif, Ena Wang, Helen Chen, William D. Merritt, Sacha Gnjatic, Kara Davis, Ignacio Wistuba, James Lindsay, Stacey Adam, Fred Ramsdell, Kellie N. Smith, Davide Bedognetti, Chen Zhao, Evan Newell, Michael Angelo, David FurmanMarta Luksza, Pier Federico Gherardini, Priti Hegde, Martin Cheever, Steven Fling, Shawn Sweeney, Hongyue Dai, Catharine Young, John M. Kirkwood, Yana Najjar, Randy Sweis, Theresa Lavallee, Holden T. Maecker, Zoe Quandt

Research output: Contribution to journalReview article

Abstract

Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomarker development and utilization, the Society for Immunotherapy of Cancer (SITC) convened a workshop, "Immuno-Oncology Biomarkers: State of the Art," on May 16-17, 2018. Topics discussed included challenges in handling biospecimens, identification and validation of new biomarkers, data sharing, and collaborating across disciplines to advance biomarker development. Panel discussions followed session presentations to help foster participant conversation and discuss future projects and collaborations. The results of the Workshop include the development of new initiatives for the SITC Biomarkers Committee.

Original languageEnglish (US)
Article number138
JournalJournal for ImmunoTherapy of Cancer
Volume6
Issue number1
DOIs
Publication statusPublished - Dec 4 2018

    Fingerprint

Keywords

  • Biomarkers
  • Cancer immunotherapy
  • Checkpoint inhibitor
  • PD-1/PD-L1

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this